Could a simpler Two-Drug HIV regimen be just as effective as three?
NCT ID NCT07678268
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial tests whether a two-drug combination (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug combination (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in people with HIV whose virus is already suppressed. The study involves 78 adult men in Mexico who have had undetectable HIV levels for at least 48 weeks. Researchers will compare how well each regimen maintains viral suppression and monitor safety over 24 and 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Darunavir/Cobicistat plus Lamivudine
- What this could lead to
- If successful, this could show that a simpler two-drug HIV regimen is as effective as the standard three-drug approach, potentially reducing pill burden and side effects.
- What could go wrong
- This is a small pilot study with only 78 participants, all men, so results may not apply to everyone. The two-drug regimen might not suppress the virus as well as the three-drug combination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIRETROVIRAL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital de Infectología "Dr Daniel Méndez Hernández" National Medical Center "La Raza", Instituto Mexicano del Seguro Social
RECRUITINGMexico City, Mexico City, 02990, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Immune-Boosting cocktail aims to free HIV patients from daily medication